BioCentury | Feb 26, 2020
Product Development

Regulatory Roundup: FDA reviewing GSK, Takeda applications for earlier lines of cancer treatment; plus Novartis, Halozyme-Genentech, MacroGenics, CSL, Lilly

FDA is reviewing four earlier or additional indications for a slate of cancer drugs, plus a first-time application for MacroGenics’ anti-HER2 mAb. The agency also approved the first quadrivalent flu vaccine and a CV application...
BC Extra | Nov 4, 2019
Clinical News

Halozyme to focus on Enhanze partnering after Phase III oncology miss

With the failure of Halozyme's lead cancer program in a Phase III trial, the company intends to exit the oncology R&D field entirely and focus on deriving partner revenue from its subcutaneous drug delivery technology...
BC Innovations | Jun 19, 2019
Distillery Therapeutics

HAS2 and NOTCH1 identified as targets in liver fibrosis induced by hepatitis B, hepatitis C and NASH

DISEASE CATEGORY: Hepatic INDICATION: Liver fibrosis; non-alcoholic steatohepatitis (NASH) Blocking hyaluronan synthesis, including via inhibition of HAS2 or its downstream effector NOTCH1, could help treat liver fibrosis. In hepatitis B, hepatitis C and NASH patients,...
BC Innovations | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
BC Innovations | Oct 11, 2018
Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample and mouse studies suggest HAPLN1 could help treat metastatic melanoma. In 192 non-metastatic melanoma patients, high regional lymphatic tissue expression of HAPLN1 correlated with survival. In a mouse model of metastatic...
BC Innovations | Sep 28, 2018
Targets & Mechanisms

Cell metabolism’s migration

As cancer metabolism undergoes a renaissance in the clinic, with compounds targeting growth factor and nutrient sensing pathways, basic research on metabolic processes in all cells is shining light on pathways that could yield new...
BioCentury | Aug 4, 2018
Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
BC Week In Review | Jan 19, 2018
Clinical News

Halozyme's PEGPH20 leads to worse OS in first-line pancreatic cancer

Halozyme Therapeutics Inc. (NASDAQ:HALO) reported that PEGPH20 plus modified FOLFIRINOX chemotherapy led to worse overall survival (OS) compared with chemotherapy alone in the Phase Ib/II S1313 trial to treat previously untreated metastatic pancreatic cancer. The...
BC Extra | Jan 17, 2018
Clinical News

First-line pancreatic cancer readout sinks Halozyme shares

Halozyme Therapeutics Inc. (NASDAQ:HALO) slipped $1.76 to $17.98 Wednesday after reporting that PEGPH20 plus modified FOLFIRINOX chemotherapy led to worse overall survival (OS) compared with chemotherapy alone in the Phase Ib/II S1313 trial to treat...
BC Week In Review | Dec 22, 2017
Company News

Alexion licenses Halozyme's drug delivery tech

Halozyme Therapeutics Inc. (NASDAQ:HALO) granted Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) a license to use its Enhanze technology to develop subcutaneous formulations of therapies against up to four targets, including a new formulation of ALXN1210. Halozyme will...
Items per page:
1 - 10 of 196